Why this Raymond James analyst is calling for a clinical reassessment of Gilead's remdesivir treatment

Raymond James is out with a critical new note which says Gilead's response to the WHO report "calls into question management's ability or willingness going forward to treat data with appropriate rigor and respect." Steve Seedhouse, the Raymond James analyst behind the note, and CNBC's Meg Tirrell join 'Power Lunch' to discuss.
Fri, Oct 16 20202:59 PM EDT